EyePoint Pharmaceuticals/$EYPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About EyePoint Pharmaceuticals
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Ticker
$EYPT
Sector
Primary listing
Employees
214
Headquarters
Website
EYPT Metrics
BasicAdvanced
$1.2B
-
-$3.17
1.79
-
Price and volume
Market cap
$1.2B
Beta
1.79
52-week high
$19.11
52-week low
$3.91
Average daily volume
1.8M
Financial strength
Current ratio
8.877
Quick ratio
8.285
Long term debt to equity
6.786
Total debt to equity
7.446
Interest coverage (TTM)
-7,376.79%
Profitability
EBITDA (TTM)
-241.125
Gross margin (TTM)
-598.45%
Net profit margin (TTM)
-739.42%
Operating margin (TTM)
-775.98%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-38.89%
Return on equity (TTM)
-72.19%
Valuation
Price to revenue (TTM)
32.76
Price to book
3.8
Price to tangible book (TTM)
3.81
Price to free cash flow (TTM)
-4.222
Free cash flow yield (TTM)
-23.68%
Free cash flow per share (TTM)
-3.323
Growth
Revenue change (TTM)
-27.50%
Earnings per share change (TTM)
36.22%
3-year revenue growth (CAGR)
-8.83%
3-year earnings per share growth (CAGR)
4.94%
What the Analysts think about EYPT
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
EYPT Financial Performance
Revenues and expenses
EYPT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for EyePoint Pharmaceuticals stock?
EyePoint Pharmaceuticals (EYPT) has a market cap of $1.2B as of March 13, 2026.
What is the P/E ratio for EyePoint Pharmaceuticals stock?
The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of March 13, 2026.
Does EyePoint Pharmaceuticals stock pay dividends?
No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next EyePoint Pharmaceuticals dividend payment date?
EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.
What is the beta indicator for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.